

Trial : NL83392.078.23

Published: 13-02-2023

Last updated: 07-12-2024

Publication withdrawn by sponsor

Ethical review	Approved WMO
Status	Other
Health condition type	Reproductive neoplasms female malignant and unspecified
Study type	Interventional

Summary

ID

NL-OMON53922

Source

ToetsingOnline

Brief title

NL83392.078.23

Condition

- Reproductive neoplasms female malignant and unspecified

Synonym

Recurrent Ovarian Cancer / Ovarian Cancer

Research involving

Human

Sponsors and support

Primary sponsor: Regeneron Pharmaceuticals, Inc.

Source(s) of monetary or material Support: Industry

Intervention

Keyword: Open-label, Ovarian Cancer

Outcome measures

Primary outcome

Publication withdrawn by sponsor

Secondary outcome

Publication withdrawn by sponsor

Study description

Background summary

Publication withdrawn by sponsor

Study objective

Publication withdrawn by sponsor

Study design

Publication withdrawn by sponsor

Intervention

Publication withdrawn by sponsor

Study burden and risks

Publication withdrawn by sponsor

Contacts

Public

Regeneron Pharmaceuticals, Inc.

US

Scientific

Regeneron Pharmaceuticals, Inc.

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Publication withdrawn by sponsor

Exclusion criteria

Publication withdrawn by sponsor

Study design

Design

Study phase:	2
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Other
Start date (anticipated):	22-04-2024

Enrollment: 21
Type: Actual

Medical products/devices used

Registration: No

Ethics review

Approved WMO
Date: 13-02-2023
Application type: First submission
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO
Date: 10-07-2023
Application type: First submission
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO
Date: 08-01-2024
Application type: Amendment
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO
Date: 04-03-2024
Application type: Amendment
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EU-CTR	CTIS2024-510783-23-00
EudraCT	EUCTR2019-003298-24-NL
ClinicalTrials.gov	NCT03564340
CCMO	NL83392.078.23